Appleby Advises Jatt II Acquisition Corp. on Go-Public Merger with Talawar TX Inc.
Appleby is advising as Cayman Islands legal counsel to JATT II Acquisition Corp., (JATT II) a special purpose acquisition company focused on building the next wave of life sciences companies, on the signing of a definitive business combination agreement with Talawar TX Inc., a biotechnology company developing potentially best-in-class bispecific antibodies that pair independent immunology & inflammatory disease drivers in a single therapy.
The business combination is expected to close in the second half of 2026, subject to customary closing conditions, including approvals from JATT II shareholders and regulators. Upon closing, the combined company expects to receive $285 million in gross proceeds. Proceeds will be funded through a combination of $60 million held in a trust account by JATT II, assuming no redemptions by JATT II’s public shareholders, and an oversubscribed $225 million concurrent private investment in public equity of common stock at $10 per share.
The combined company will operate as Talawar Therapeutics and is expected to trade on the Nasdaq Capital Market under the ticker symbol “TLWR.”
Appleby is advising on all Cayman Islands legal aspects of the transaction, drawing on its extensive experience in cross-border mergers and capital markets transactions.
The Appleby Mergers and Acquisitions team was led by Partner Alexandra Low, Paralegal Sophia Cunningham and Articled Clerk Emily McIntyre with other members of the corporate team.
Appleby continues to play a key role in major public merger and acquisitions and public-market transactions worldwide.
